Date of Publication: 02-02-2026
INTELLIGENCE OVERVIEW
Agency: European Medicines Agency (EMA)
The European Medicines Agency (EMA) has published a reflection paper on the qualification of non-mutagenic impurities, providing scientific guidance on how such impurities should be assessed, justified, and controlled during drug development and lifecycle management .
Industry Impact
This guidance is important for MAHs, API manufacturers, and pharmaceutical developers as it:
- Clarifies regulatory expectations for qualifying non-mutagenic impurities
- Promotes a risk-based, science-driven approach instead of default conservative limits
- Supports more flexible quality strategies during development and post-approval changes
- Reduces the risk of regulatory queries and delays related to impurity control
Overall, the reflection paper improves regulatory predictability and enables more efficient impurity management across the EU pharmaceutical lifecycle.
https://www.ema.europa.eu/en/qualification-non-mutagenic-impurities-scientific-guideline